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Abstract
Background: In the setting of chronic liver injury in humans, epidermal growth factor (EGF) and EGF receptor (EGFR) 
are up-regulated and have been proposed to have vital roles in both liver regeneration and development of 
hepatocellular carcinoma (HCC). Chronic liver injury also leads to hepatic stellate cell (HSC) differentiation and a novel 
subpopulation of HSCs which express CD133 and exhibit properties of progenitor cells has been described in rats. The 
carbon tetrachloride (CCl4)-induced mouse model has been historically relied upon to study liver injury and 
regeneration. We exposed mice to CCl4 to assess whether EGF and CD133+ HSCs are up-regulated in chronically 
injured liver.
Methods: CCl4 in olive oil was administered to strain A/J mice three times per week by oral gavage.
Results: Multiple well-differentiated HCCs were found in all livers after 15 weeks of CCl4 treatment. Notably, HCCs 
developed within the setting of fibrosis and not cirrhosis. CD133 was dramatically up-regulated after CCl4 treatment, 
and increased expression of desmin and glial fibrillary acidic protein, representative markers of HSCs, was also 
observed. EGF expression significantly decreased, contrary to observations in humans, whereas the expression of 
amphiregulin, another EGFR ligand, was significantly increased.
Conclusions: Species-specific differences exist with respect to the histopathological and molecular pathogenesis of 
chronic liver disease. CCl4-induced chronic liver injury in A/J mice has important differences compared to human 
cirrhosis leading to HCC.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and is the third leading cause of
cancer mortality [1]. Eighty percent of HCCs develop in
the context of chronic liver diseases, as chronic liver
injury generally induces liver fibrosis, followed by cirrho-
sis [2]. In an attempt to model this process, carbon tetra-
chloride (CCl4) has been widely used to experimentally
induce liver injury in rodents. A single dose of CCl4 leads
to centrizonal necrosis and steatosis [3], while prolonged
administration leads to liver fibrosis, cirrhosis, and HCC
[4]. CCl4 impairs hepatocytes directly by altering the per-
meability of the plasma, lysosomal, and mitochondrial
membranes. Highly reactive free radical metabolites are
also formed by the mixed function oxidase system in
hepatocytes via CYP2E1, causing severe centrilobular
necrosis [5,6]. This model has been used extensively to
examine the pathogenesis of cirrhosis.
Liver fibrosis is the pathologic result of ongoing chronic
inflammatory liver diseases and is characterized by
hepatic stellate cell (HSC) proliferation and differentia-
tion to myofibroblast-like cells, which deposit extracellu-
lar matrix (ECM) and collagen. Quiescent HSCs are
vitamin A storing cells in the space of Disse, and they
account for about 15% of the total number of liver cells
[7]. The activation of HSCs is mediated by reactive oxy-
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gen species and various cytokines, including transform-
ing growth factor (TGF)-β, tumor necrosis factor (TNF)-
α, and platelet-derived growth factor (PDGF), as well as
other factors which are released from the damaged hepa-
tocytes and activated Kupffer cells [8]. The activated
HSCs produce large amounts of ECM components, such
as laminin and collagen type IV, in an accelerated fashion,
resulting in fibrotic change of the liver. The number of
HSCs was found to be increased in alcoholic liver disease
and in other animal models of chronic liver disease [8].
HSCs are further characterized by their stellate-shaped
morphology and expression of desmin and glial fibrillary
acidic protein (GFAP). A novel subpopulation of HSCs in
rats has been described to exhibit properties of progeni-
tor cells and express CD133, originally thought to be a
marker of endothelial progenitor cells (EPCs),
hematopoietic stem cells, and other stem cells [9]. This
finding gave rise to the hypothesis that CD133+ HSCs are
up-regulated in chronically injured liver.
Epidermal growth factor (EGF), a polypeptide mitogen,
and its tyrosine kinase receptor (EGFR) have been pro-
posed to have vital roles in liver regeneration and trans-
formation [10,11]. EGF and EGFR are highly elevated in
human cirrhotic livers [12]. However, to the best of our
knowledge, the expression of EGF and EGFR in the
injured liver in mouse models has not been fully investi-
gated.
In the current study, we exposed mice to CCl4 to create
fibrosis, cirrhosis, and HCC and assessed histopathology,
EGF expression, and HSC populations. We observed that
CD133+ HSCs are recruited during chronic liver injury in
CCl4-treated mice. Multiple HCCs were found in the liv-
ers of all mice after 15 weeks of CCl4 treatment; however,
the pathological findings and EGF expression patterns in
the injured liver were different from those previously
reported in humans, suggesting that species-specific dif-
ferences exist with respect to the histopathological and
molecular pathogenesis of chronic liver injury.
Methods
Animals and Experimental Design
Strain A/J male mice at approximately 5 weeks of age
were purchased from Jackson Laboratory (Bar Harbor,
ME). As shown in Figure 1, all mice were randomly
assigned to two groups: a control group (n = 15) and a
CCl4 group (n = 25). Mice were treated three times a week
for 17 weeks with either 0.04 cc of a 40 percent solution
of CCl4 (Sigma, St. Louis, MO) in olive oil or with vehicle
by oral gavage. Mice were subsequently sacrificed at the
indicated times after a one-week washout to eliminate
acute effects of CCl4. The liver was sectioned and fixed in
phosphate-buffered 10% formaldehyde for histological
analysis. The remaining portions of the liver were col-
lected in RNase-free tubes and snap-frozen in liquid
nitrogen. Mice were classified into three groups, depend-
ing on the time of sacrifice: Time point I (4-6 weeks),
Time point II (15-17 weeks), Time point III (24-30
weeks).
Histopathological Examination
Each formaldehyde-fixed sample was embedded in paraf-
fin, cut into 5 μm-thick sections and stained with hema-
toxylin-eosin (H-E), Masson's trichrome and Sirius red
according to standard procedures. Those from CCl4 and
control groups at Time point II were stained with anti-
bodies for CD133, desmin and alpha-smooth muscle
actin (α-SMA) (all from Abcam; Cambridge, MA)
according to the manufacturer's instructions. All slides
were reviewed by the same pathologist.
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction (PCR)
was carried out as described previously [11]. Briefly, total
RNA was extracted from a small piece of frozen mouse
liver using TRIzol (Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions.
The mRNA expression of EGF, EGFR, transforming
growth factor-alpha (TGF-α), heparin-binding EGF-like
growth factor (HB-EGF), amphiregulin (AREG), desmin,
GFAP, CD133 and vascular endothelial growth factor
receptor 2 (VEGFR2) was analyzed. The mRNA expres-
sion was normalized to the expression of GAPDH. Primer
sequences were as follows: SEQ NO.1 EGF forward
(NM_010113.1 87-106 bp) GGCTTGGAACTTTCCAT-
CAA, SEQ NO.2 EGF reverse (NM_010113.1 333-314 bp)
CAGGTCCTTCTGCACCTCTC, SEQ NO.3 EGFR for-
ward (NM_207655.1 349-368 bp) GGCGTTGGAG-
GAAAAGAAAG, SEQ NO.4 EGFR reverse
(NM_207655.1 471-452 bp) TTCCCAAGGACCACT-
TCACA, SEQ N0.5 TGF-α forward (NM_031199.1 2395-
2414 bp) CAGGGAGCAACACAAATGGA, SEQ N0.6
TGF-α reverse (NM_031199.1 2491-2471 bp) AGCCTC-
CAGCAGACCAGAAA, SEQ NO.7 HB-EGF forward
(NM_010415.2 1147-1166 bp) GAAAGCAGGATC-
GAGTGAGC, SEQ NO.8 HB-EGF reverse
(NM_010415.2 1369-1350 bp) CTTGCGGCTACTT-
GAACACA, SEQ NO.9 AREG forward (NM_009704.3
739-758 bp) GACTCACAGCGAGGATGACA, SEQ
NO.10 AREG reverse (NM_009704.3 987-968 bp)
GGCTTGGCAATGATTCAACT, SEQ NO.11 desmin
forward (NM_010043.1 1723-1742 bp) AGCTCAAGT-
CATCGCCCTTC, SEQ. NO. 12 desmin reverse
(NM_010043.1 1801-1781 bp) GCAGATCCCAACAC-
CCTCTC, SEQ NO.13 GFAP forward (NM_010277.1
1078-1097 bp)AACCGCATCACCATTCCTGT, SEQ
NO.14 GFAP reverse (NM_010277.1 1214-1196 bp)
ACCTCACCATCCCGCATCT, SEQ NO.15 CD133 for-Fujii et al. BMC Gastroenterology 2010, 10:79
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ward (NM_008935.1 1698-1717 bp) GAAAAGTT-
GCTCTGCGAACC, SEQ NO.16 CD133 reverse
(NM_008935.1 1893-1874 bp) TCTCAAGCTGAAAA
GCAGCA, SEQ NO.17 VEGFR2 forward (NM_010612.1
3574-3593 bp) ATGCGGGCTCCTGACTACAC, SEQ
NO.18 VEGFR2 reverse (NM_010612.1 3683-3664 bp)
CCCAAATGCTCCACCAACTC, SEQ NO.19 GAPDH
forward (NM_008084 543-562 bp) AACTTTGGCATT-
GTGGAAGG, SEQ NO.20GAPDH reverse (NM_008084
765-746 bp) ACACATTGGGGGTAGGAACA. All reac-
tions were performed in duplicate, and the experiment
was repeated to ensure reproducible results.
Enzyme-Linked Immunosorbent Assay (ELISA)
Liver tissue samples were homogenized in RIPA Buffer
(Boston BioProducts, Worcester, MA) containing pro-
tease inhibitors (Sigma). Homogenates were centrifuged
twice at 10,000 × g for 30 minutes at 4°C, and the pellets
were discarded. Protein concentration was determined
using the bicinchoninic acid (BCA) method (Pierce
Chemical Co., Rockford, IL). The protein level of EGF
was examined using a Quantikine Immunoassay kit (R&D
Systems Inc., Minneapolis, MN) according to the manu-
facturer's instructions. All samples were measured in
triplicate.
Western Blotting
Western blotting was carried out as described previously
[11]. Briefly, cellular lysates (35 μg) were prepared in
Laemmli's reducing sample buffer (Boston BioProducts),
separated by electrophoresis on 4-20% polyacrylamide
gradient gels (Cambrex Bio Science, Walkersville, MD).
Membranes were incubated overnight at 4°C with pri-
mary antibodies raised against EGFR, phospho-EGFR
(Tyr 1068) and proliferating cell nuclear antigen (PCNA)
(all from Cell Signaling Technology, Beverly, MA) and
Figure 1 Flow diagram depicting treatment of strain A/J mice with carbon tetrachloride (CCl4). (A) Schema. Mice were treated three times per 
week for 17 weeks by oral gavage with 0.04 cc of a 40% solution of CCl4 in olive oil or the vehicle control. (B) Experimental observations. Fibrosis was 
evident 15 weeks after initial CCl4 treatment, and hepatocellular carcinomas (HCCs) were identified macroscopically in 100% of mice after 17 weeks. 
Mice were classified into three groups depending on the time of sacrifice (Time point I (4-6 weeks), Time point II (15-17 weeks), Time point III (24-30 
weeks)). (C) Representative macroscopic pictures of livers from mice sacrificed at Time point III are shown.Fujii et al. BMC Gastroenterology 2010, 10:79
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then incubated with appropriate secondary antibodies for
1 h at room temperature. An antibody directed against β-
actin (Abcam) was used to verify equal loading. Each
western blot was repeated to ensure reproducible results.
Statistical Analysis
The relative mRNA expression levels were calculated
from the quantified data. An unpaired t test was used to
analyze the differences, and a non-parametric test was
used (Mann-Whitney U test) if the distribution was
abnormal. All the statistical analyses were performed
using Stat View 5.0 (Abacus Concepts, Berkeley, CA).
Data are expressed as mean ± SD. P < 0.05 denoted the
presence of a statistically significant difference.
Results
Histological Analysis
As shown in Figure 1A, mice either received CCl4 solu-
tion via oral gavage three times per week or olive oil alone
as control. In the CCl4 group, mice became lethargic and
lean, and their fur became lusterless. One or multiple
nodules, as many as 10 occurring in one liver, were found
macroscopically on the surface of the entire liver in 100%
of mice after 15 weeks of CCl4 treatment (Figure 1B, C).
Tumors size varied from 0.1 to 1.2 cm in diameter.
Liver samples were stained with H-E and Masson's
trichrome to evaluate histopathologic changes and tissue
fibrosis (Figure 2A, B). H-E staining of liver tissue from all
control mice at each time point revealed normal cellular
architecture (Figure 2A). Liver tissue from CCl4 Group at
Time point I (4-6 weeks) demonstrated some cellular
damage and centrilobular congestion with no infiltration
of inflammatory cells. Liver tissue from CCl4 Group at
Time point II (15-17 weeks) demonstrated increased
mitotic activity, intense neutrophilic infiltration, exten-
sive fatty changes and severe centrilobular necrosis. Well-
differentiated HCCs and severe fatty changes were
observed in livers from the CCl4 Group at Time point III
(24-30 weeks). Masson's trichrome staining of the liver
was performed to assess collagen distribution (Figure 2B).
All control mice at each time point revealed a normal dis-
tribution of collagen. Extensive collagen deposition and
pseudolobular formation was only evident in liver tissue
from CCl4 Group at Time point II. When examined by a
pathologist, the livers were determined to have bridging
fibrosis (Ishak score 3-4). As previously mentioned, well-
differentiated HCCs were confirmed microscopically in
all mice after 15 weeks (Time point II) of CCl4 treatment;
however, most notably, no evidence of cirrhosis (i.e. the
presence of regenerative nodules) was identified in these
livers, even in those with HCC. Given that the goal of this
study was to create HCC in the setting of cirrhosis and
HCCs had already developed in the absence of cirrhosis,
CCl4 treatment was stopped at this point. Interestingly,
the degree of inflammation and collagen deposition
decreased at Time point III, suggesting that the liver
repaired itself.
T o further assess the extent of fibrosis/cirrhosis after
CCl4 treatment, Sirius red staining was performed on
liver sections from each time point (Figure 3). The results
were similar to the Masson's trichrome stains. Control
mice had a normal distribution of collagen, whereas those
treated with CCl4 at Time point I demonstrated early
signs of fibrosis. Mice treated with CCl4 at Time point II
demonstrated bridging fibrosis and those at Time point
III had less collagen deposition suggesting again that the
liver repaired itself.
EGF and EGFR Expression
We examined 11 control livers (Time point I, II, III; n = 4,
n = 2, n = 5, respectively), 4 damaged but non-fibrotic liv-
ers (Time point I), 5 fibrotic livers (Time point II), and 8
non-cancerous livers (Time point III) for EGF mRNA
expression by quantitative real-time PCR. EGF mRNA
expression markedly decreased during liver injury (Figure
4A). To investigate EGF protein levels, ELISA for EGF
was conducted in the same liver samples. EGF protein
expression in the injured liver was significantly lower
than in the normal liver (Figure 4B). EGFR mRNA
expression also decreased significantly with increasing
degree of liver injury (Figure 4C). Interestingly, we
observed that total EGFR levels decreased with CCl4
administration while p-EGFR levels increased. The
decrease in total EGFR in the presence of increased p-
EGFR is likely a result of ligand-mediated receptor endo-
cytosis [13]. This is consistent with decreased total EGFR
protein expression observed in proliferating hepatocytes
[14] which we confirmed by increased PCNA expression
in response to CCl4 administration (Figure 4D). A corre-
lation appears to exist then between p-EGFR levels and
PCNA and therefore probably hepatocyte proliferation.
Since we observed no increase in EGF expression, we
examined the expression of several other EGFR ligands
including HB-EGF, AREG and TGF-α, which has been
reported to play an essential role in the regenerating liver
[15]. TGF-α mRNA expression in livers treated with CCl4
was significantly higher than in control livers (Figure 5A),
while HB-EGF levels did not change (Figure 5B). AREG
was dramatically increased in livers treated with CCl4
(Figure 5C).
CD133 Expression
To evaluate HSCs in injured livers, quantitative real-time
PCR was performed for desmin and GFAP, known to be
representative markers of HSCs [16]. Increased expres-
sion of both desmin and GFAP mRNA was observed inFujii et al. BMC Gastroenterology 2010, 10:79
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Figure 2 Histopathological examination of mouse livers revealed fibrosis and HCC but no evidence of cirrhosis. (A) Liver tissue from all control 
mice at each time point gavaged with olive oil alone revealed normal cellular architecture (upper, H-E, original magnification ×40). Liver tissue from 
CCl4 Group at Time point I revealed some damage of liver cells and centrilobular congestion with no infiltration of inflammatory cells (bottom left, H-
E, original magnification ×200). Liver tissue from CCl4 Group at Time point II had increased mitotic activity (arrows), intense neutrophilic infiltration, 
extensive fatty changes and severe centrilobular necrosis (bottom middle, H-E, original magnification ×600). Liver tissue from CCl4 Group at Time point 
III revealed well-differentiated HCCs (arrowheads) with severe fatty changes (bottom right, H-E, original magnification ×40). High-power view (×200) 
of tumor cells is shown. (B) Masson's trichrome staining of the liver from all control mice at each time point revealed normal lobular architecture and 
a normal distribution of collagen (upper). Masson's trichrome staining of liver tissue from CCl4 Group at Time point II revealed extensive collagen de-
position and pseudolobular formation, suggesting liver fibrosis (bottom middle). The degree of collagen deposition decreased at Time point III (bot-
tom right). (original magnification ×40).Fujii et al. BMC Gastroenterology 2010, 10:79
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the more extensively injured liver samples (Figure 6A, B).
Furthermore, CD133 was also dramatically up-regulated
in the livers of CCl4-treated mice (Figure 6C). Upon with-
drawal of CCl4, the expression of CD133 returned to con-
trol levels in the surrounding normal tissues but
remained elevated in the tumors. CD133 positive cells
probably correspond to HSCs as an immunohistochemi-
cal study revealed that CD133, desmin and α-SMA (a
marker for activated HSCs) localized to the same regions
in CCl4-treated mouse livers (Figure 7). Further, the
mRNA expression of VEGFR2, reported to be one of the
surface markers of EPCs, was not altered (Figure 6D).
In order to exclude the possibility that CCl4 simply pro-
motes CD133 expression in existing parenchyma cells, an
in vitro study was also conducted. Hepa 1-6 (mouse hepa-
toma), THLE-5B (non-tumorigenic human liver), HepG2
(human hepatoblastoma) and SNU-182 (human hepa-
toma) cell lines were treated with 4 mM CCl4 for 24
hours, and CD133 mRNA expression was determined.
CCl4 treatment did not increase CD133 expression in
human or mouse cell lines or in non-tumorigenic or can-
cer cell lines (data not shown). Further, in this small sam-
pling, no differences in CD133 expression were seen
between non-tumorigenic and tumorigenic cell lines
from the same species.
Discussion
CCl4-induced toxicity and its mechanisms have been
extensively investigated after oral administration to
rodents. A large number of rat models have been
reported to develop both liver cirrhosis and HCC using
CCl4 or diethylnitrosamine. In the current study, we gen-
erated well-differentiated HCCs in the livers of all CCl4-
treated strain A/J mice. Fibrosis but not cirrhosis was
identified in these livers, even in those with HCCs. The
cessation of oral gavage of CCl4  after 17 weeks may
explain why cirrhosis did not develop although HCC
clearly developed before any signs of cirrhosis. In previ-
ous reports of a rat model, liver cirrhosis induced by toxic
agents preceded the development of HCC, like in humans
[17,18]. In this study, HCCs were obviously generated in
fibrotic, not cirrhotic, livers.
Many investigators have previously reported their find-
ings in mice treated with CCl4, each with different mouse
strains and CCl4 administration schedules. We therefore
reviewed eight published reports of mouse models of
liver "cirrhosis" induced only by CCl4 to assess fibrosis,
regenerative nodules, and cirrhosis [19-26]. One report of
a transgenic mouse model was also reviewed [27]. Of the
nine models previously reported in the literature, only the
model by Xue et al. shows incomplete cirrhosis (Ishak
Figure 3 Histopathological examination of mouse livers by Sirius red staining. Sirius red staining of the liver from all control mice at each time 
point revealed normal lobular architecture and a normal distribution of collagen (upper). Sirius red staining of liver tissue from CCl4 Group at Time 
point II revealed extensive collagen deposition and pseudolobular formation, indicative of bridging fibrosis (bottom middle). The degree of collagen 
deposition decreased at Time point III (bottom right). (original magnification ×40).Fujii et al. BMC Gastroenterology 2010, 10:79
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Figure 4 EGF and EGFR expression was significantly decreased in mice treated with CCl4. EGF expression was determined by (A) quantitative 
real-time PCR and (B) ELISA. The mRNA expression of (C) EGFR was examined by quantitative real-time PCR. (D) Western blot analysis of three repre-
sentative liver tissues at each Time point for EGFR, p-EGFR (Y1068), PCNA and β-actin. Each value represents the mean ± SD. *P < 0.05, **P < 0.01 and 
***P < 0.001 compared with respective control mice (Time point I: Control group n = 4, CCl4 Group n = 4; Time point II: Control group n = 2, CCl4 Group 
n = 5, Time point III: Control group n = 5, CCl4 Group n = 9).
Figure 5 TGF-α and AREG expression was significantly increased in mice treated with CCl4. (A) TGF-α, (B) HB-EGF and (C) AREG expression were 
determined by quantitative real-time PCR. Each value represents the mean ± SD. *P < 0.05 and **P < 0.001 compared with respective control mice 
(Time point I: Control group n = 4, CCl4 Group n = 4; Time point II: Control group n = 2, CCl4 Group n = 5, Time point III: Control group n = 5, CCl4 Group 
n = 9).Fujii et al. BMC Gastroenterology 2010, 10:79
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score = 5) with portal fibrosis, bridging fibrosis, and
regenerative nodules [23,28]. Two other models show
changes similar to ours [19,24], all the others showed only
l i m i t e d  p o r t a l  f i b r o s i s  a n d  b r i d g i n g  f i b r o s i s  w i t h  n o
regenerative nodules. Thus, it may be more difficult to
induce cirrhosis in mice.
The mechanism mobilizing the normally quiescent
hepatocyte into mitogenesis in injured liver is poorly
understood, although accumulating data suggest that
EGF and TGF-α, specific ligands of EGFR, play a central
role in initiating and/or sustaining the early growth
response program [15,28,29]. We obtained evidence that
both mRNA and protein expression of EGF significantly
decreased during liver injury, but increased during repair
after the withdrawal of CCl4. The transcription of EGF
was shown to be extremely low in control livers but was
highly elevated in cirrhotic livers of human patients, and
EGF expression was increased significantly during the
course of cirrhosis development in a rat model [12,30].
Therefore, histopathological changes and EGF expression
patterns observed in this mouse model were different
from those previously reported in rats and humans. Con-
sistent with previously reported rat models of liver cir-
rhosis, EGFR expression was shown to decrease in this
mouse study, whereas it has been reported to increase in
human cirrhosis patients [31,32]. However, these results
are difficult to interpret as decreased levels of total EGFR
observed in animal models might be due to ligand-medi-
ated receptor endocytosis in response to elevated signal-
ing.
Combined with our histopathological analysis of previ-
ously published reports, our results indicate that there
are species-specific differences in liver regeneration in
response to cytokines and growth factors. Previous inves-
Figure 6 CCl4-induced fibrosis in mice is associated with increased presence of hepatic stellate cells (HSCs). The presence of HSCs was deter-
mined by quantitative real-time PCR for the following markers: (A) desmin, (B) GFAP, and (C) CD133. The mRNA expression of these markers was sig-
nificantly up-regulated in the fibrotic livers of CCl4-treated mice. Upon withdrawal of CCl4, the expression of CD133 returned to control levels in the 
surrounding normal tissues but remained elevated in the tumors (C). No increase was seen by quantitative real-time PCR for (D) VEGFR2, one of the 
surface markers of EPCs. Each value represents the mean ± SD. *P < 0.05, **P < 0.01 and ***P = 0.0001 compared with respective control mice (Time 
point I: Control group n = 4, CCl4 Group n = 4; Time point II: Control group n = 2, CCl4 Group n = 5, Time point III: Control group n = 5, CCl4 Group (Non-
tumor part) n = 9, CCl4 Group (HCC part) n = 5).Fujii et al. BMC Gastroenterology 2010, 10:79
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tigators have provided evidence of the differences in the
response to hepatotoxicity in the livers of rodents. High
levels of inhalation exposure to CCl4 resulted in liver cir-
rhosis in rats but in neither fibrosis nor cirrhosis in mice
[33]. Furthermore, inflammation of the liver was almost
absent in rats after common bile duct ligation but was
more pronounced in mice [34]. It was also reported that
the lack of circulating EGF in sialoadenectomized mice
did not decrease the proportion of hepatocytes that repli-
cate during liver regeneration after partial hepatectomy
[35], whereas removal of the salivary glands in rats led to
complete blockage of liver regeneration [36]. It would
appear that other EGFR ligands might be critically
involved in liver regeneration in mice instead of EGF
[28,37]. For example, both TGF-α and AREG increased in
injured livers in this study. TGF-α has previously been
shown to increase in previous reports of rats and humans
and AREG has previously been shown to participate in
the development of mouse liver fibrosis [38]. Importantly,
AREG has also been shown to contribute to the neoplas-
tic phenotype of human HCC cells (Castillo 2006 Cancer
Research) and therefore the CCL4 model could be used
to further study the role of AREG in hepatocarcinogene-
sis.
We observed that the expression of both desmin and
GFAP, known to be markers of HSCs, were significantly
elevated in injured liver samples. This finding implicates
increased numbers of HSCs in the livers of CCl4-treated
mice. In a recent study, Kordes et al. demonstrated that
20-40% of HSCs expressed CD133 and exhibited proper-
ties of progenitor cells in rats [9]. Motivated by this
report, we also examined CD133 expression in the
injured livers of mice. The mRNA expression of CD133
was observed to be up-regulated in more injured liver as
was desmin and GFAP. Further, immunohistochemical
staining revealed that CD133, desmin and α-SMA local-
i z e d  t o g e t h e r  i n  C C l 4-treated mice livers. CD133 has
been recognized as a cell surface marker of stem/progeni-
tor cells. However, the mRNA expression of VEGFR2,
reported to be one of the markers of both early and
mature EPCs was not associated with the degree of the
liver injury. Our results indicated that CD133 positive
cells probably correspond to HSCs, not EPCs, and that
CD133+ HSCs increased through chronic liver injury in
CCl4-treated mice. Finally, CD133 expression returned to
control levels in the surrounding non-cancerous tissues
but remained elevated in HCCs.
CD133+ cells have been identified in the ductular reac-
tions of chronically damaged human livers [39]. CD133
has been implicated as a marker for cancer stem cells of
epithelial origin [40], and consistent with this, CD133+
cells isolated from human HCC cell lines have been
reported to have cancer stem cell properties [41,42]. Fur-
ther, CD133 expression has been reported to be associ-
ated with poor disease-free survival in HCC patients but
was negatively associated with HBsAg, implicating a non-
Figure 7 CD133, desmin and α-SMA localize together in CCl4-treated mouse livers. Liver sections from CCl4 and control groups at Time point II 
were stained with antibodies for CD133, desmin and α-SMA.Fujii et al. BMC Gastroenterology 2010, 10:79
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viral origin of CD133 expression in HCC. Here, we have
shown that a chemical toxicity induces CD133 expression
in the liver. Overall, our results suggest an association
between CD133 upregulation and tumor generation
although details must be elucidated by further investiga-
tion.
Our results suggest that the use of CCl4-induced
chronic liver injury in mice has important differences
compared to human cirrhosis. In humans, HCCs typically
develop within the setting of cirrhosis; however, in this
study, no evidence of cirrhosis was seen, and HCCs devel-
oped within a setting of fibrosis. Furthermore, EGF
expression decreased significantly during chronic liver
injury, whereas it has been shown to increase during
development of human cirrhosis. These results suggest
that species-specific differences exist with respect to the
histopathological and molecular pathogenesis of chronic
liver disease. The dramatic up-regulation of CD133 is a
notable finding, and the contribution of CD133+ HSCs to
liver regeneration and tumor progression await further
studies in rodents and humans.
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